Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride

Clinical Pharmacokinetics

Volumn 48, Issue 5, 2009, Pages 303-311

  Padhi, Desmond ^a   Harris, Robert ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CARBONATE; CINACALCET; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIPRAMINE; ERYTHROMYCIN; FLECAINIDE; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANTOPRAZOLE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; RAPAMYCIN; SEVELAMER; TACROLIMUS; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; VINBLASTINE; VITAMIN D; WARFARIN;

AGE; AREA UNDER THE CURVE; BODY WEIGHT; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ETHNICITY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; KIDNEY DISEASE; LIPID DIET; LIVER DISEASE; LOW FAT DIET; NAUSEA; PARATHYROID CARCINOMA; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PHARMACODYNAMICS; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SEX; SINGLE DRUG DOSE; URINE; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES;

EID: 67650248933     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-200948050-00002     Document Type: Review

References (49)

1. Silverberg SJ, Bilezikian JP. The diagnosis and management of asymptomatic primary hyperparathyroidism. Nat Clin Pract Endocrinol Metab 2006 Sep; 2 (9): 494-503
2. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperpara-thyroidism. Kidney Int Suppl 1999 Dec; 73: S14-9
3. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperpara- thyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006 Jan; 21 (1): 171-7
4. Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 2001 Feb; 86 (2): 485-93
5. US Renal Data System. USRDS 2007 annual data report. Bethesda (MD): National Institute of Diabetes and Digestive Kidney Diseases, 2007 [online]. Available from URL: http://www.usrds.org/atlas-2007.htm [Accessed 2009 Mar 26]
6. Martinez I, Saracho R, Montenegro J, et al. The importance ofdietary calcium and phosphorous in the secondary hyperparathyroidism ofpatients with early renal failure. Am J Kidney Dis 1997 Apr; 29 (4): 496-502
7. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005 Feb; 288 (2): F253-64
8. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005 Mar; 67 (3): 1179-87
9. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15 (8): 2208-18
10. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000 May 18; 342 (20): 1478-83
11. Verberckmoes SC, Persy V, Behets GJ, et al. Uremia-related vascular calcification: more than apatite deposition. Kidney Int 2007 Feb; 71 (4): 298-303
12. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000 Jul; 58 (1): 396-9
13. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006 Jul; 17 (7): 2034-47
14. Raggi P. Cardiovascular calcification in end stage renal disease. Contrib Nephrol 2005; 149: 272-8
15. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38 (4): 938-42
16. Gueerin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000 Jul; 15(7): 1014-21
17. Blacher J, Safar ME, Guerin AP, et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003 May; 63 (5): 1852-60
18. Locatelli F, Cannata-Andia JB, Drueke TB, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphatemia. Nephrol Dial Transplant 2002; 17 (5): 723-31
19. Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004 Feb; 308 (2): 627-35
20. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16 (3): 800-7
21. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 Oct; 42 (4 Suppl. 3): S1-201
22. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathy-roidism. J Clin Endocrinol Metab 2005 Jan; 90 (1): 135-41
23. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003 Dec; 88 (12): 5644-9
24. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350 (15): 1516-25
25. Padhi D, Salfi M, Harris RZ. The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals. Am J Ther 2007 May-Jun; 14 (3): 235-40
26. Sensipar® (cinacalcet) tablets: US prescribing information. Thousand Oaks (CA): Amgen Inc., 2008 Dec [online]. Available from URL: http://www.amgen.com/pdfs/misc/sensipar-pi.pdf [Accessed 2009 Mar 26]
27. Harris RZ, Padhi D, Marbury TC, et al. Pharmacokinetics, pharmaco-dynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004; 44 (6): 1070-6
28. European Medicines Agency. Mimpara: European public assessment report. Scientific discussion [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/mimpara/12029804en6.pdf [Accessed 2009 Mar 26]
29. Bajpai M, Esmay J, Chi V, et al. In vitro metabolism and prediction of drug-drug interactions of the calcimimetic agent cinacalcet HCl [abstract]. Drug Metab Rev 2005; 37 Suppl. 2: 124
30. Harris RZ, Salfi M, Posvar E, et al. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol 2007 Feb; 63 (2): 159-63
31. Harris RZ, SalfiM, Sullivan JT, et al. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet 2007; 46 (6): 495-501
32. Padhi D, Salfi M, Erbeck N, et al. Cinacalcet HCl does not affect CYP3A Activity, a metabolic pathway for commonly used immunosuppressive agents [abstract no. T-PO-1602]. World Congress of Nephrology; 2007 Apr 21-25; Rio de Janeiro 33.
33. Kumar GN, Sproul C, Poppe L, et al. Metabolism and disposition of calci-mimetic agent cinacalcet HCl in humans and animal models. Drug Metab Dispos 2004 Dec; 32 (12): 1491-500
34. Padhi D, Harris RZ, Salfi M, et al. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara). Clin Pharmacokinetics 2005; 44 (5): 509-16
35. Padhi D, Harris R, Salfi M, et al. The pharmacokinetics of cinacalcet HCl are not altered by renal impairment or mode of renal replacement therapy [abstract no. M477]. World Congress of Nephrology; 2003 Jun 8-12; Berlin
36. Ohashi N, Uematsu T, Nagashima S, et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol 2004 Jun; 57 (6): 726-34
37. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis- associated diseases in the United States, 2002. Semin Dial 2005 Jan-Feb; 18(1): 52-61
38. Padhi D, Harris RZ, Salfi M, et al. Pharmacokinetics and pharmaco-dynamics of cinacalcet in hepatic impairment: phase I, open-label, parallel- group, single-dose, single-centre study. Clin Drug Investig 2008; 28 (10): 635-43
39. Tveit DP, Hypolite IO, Hshieh P, et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 2002 May; 39 (5): 1011-7
40. Falck P, Vethe NT, Asberg A, et al. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008 Mar; 23 (3): 1048-53
41. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003 May; 43 (5): 443-69
42. Hartmann M, Theiss U, Huber R, et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996 Jun; 10 (3): 359-66
43. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997 Aug; 17 (4): 284-91
44. Preskorn SH. Clinically relevant pharmacology ofselective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 Suppl. 1: 1-21
45. Padhi D, Sullivan JT. Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin. Drugs R D 2007; 8 (2): 79-87
46. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002 Apr; 13 (4): 1017-24
47. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003 Mar; 14 (3): 575-83
48. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63 (1): 248-54
49. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005 Feb; 67 (2): 760-71